Page 498«..1020..497498499500..510520..»

John Dick and Zulfiqar Bhutta win Canada Gairdner Awards – University of Toronto

Posted: April 6, 2022 at 2:04 am

Two researchers at the University of Toronto and its hospital partners one a stem cell biologist, the other a global health researcher have been honoured with 2022Canada Gairdner Awards,the countrys most prestigious awards for medical and health science.

John Dickwas recognized with a Gairdner International Awardfor the discovery of leukemic stem cells and later work on the diagnosis and treatment of acute myeloid leukemia. He first received the news fromJanet Rossant,president and scientific director of the Gairdner Foundation, earlier this year.

When Janet called, it was definitely an Oh my gosh moment, said Dick, a professor ofmolecular geneticsat U of Ts Temerty Faculty of Medicine and a senior scientist atPrincess Margaret Cancer Centre, University Health Network.

I recall being asked to sit on an evaluation panel for the Gairdners in the early 1990s, not long after setting up my lab in Toronto. That seemed like the epitome of achievementand I never imagined in my wildest dreams that one day Id receive a Gairdner award.

The John Dirks Canada Gairdner Global Health Award went to Zulfiqar Bhuttafor his research on community-based and policy interventions in child and maternal health, especially among vulnerable populations.

Im very pleased and grateful, said Bhutta, a professor in the departments ofnutritional sciencesandpediatricsat Temerty Medicine and at theDalla Lana School of Public Health, and the director of theCentre for Global Child Healthand a senior scientist at The Hospital for Sick Children.

There are not many awards for research in global or public health, and the Gairdners occupy a special place in Canada and globally, said Bhutta, who moved to Toronto in 2013 and maintains a research group at theAga Khan Universityin Pakistan. It really is a pinnacle and most humbling.

Dick and his lab were the first to discover and describe leukemia stem cells, which can self-renew and drive both cancer growth and relapse after treatment.

Those findings have led to new clinical approaches for acute myeloid leukemia and related blood cancers, and spurred research on the role of stem cells in solid tumours of the colon, breast and brain, among other sites.

Dick said he didnt set out to discover leukemia stem cells, but instead began by plugging away at basic science on the blood system in mice, experimenting with ways to put genes into stem cells.

In a key advance in the late 1980s, Dicks lab developed a way to transplant human blood stem cells into immune-deficient mice. This xenograft assay was a world-firstand enabled Dick and other researchers to track and test the human cells growth and replication, albeit in the living system of the mouse.

At the same time, Dicks lab created the first xenograft models of human leukemiaand developed a method to purify leukemia stem cells, allowing for detailed comparisons of those cells and leukemia cells without stem-like properties.

Most people thought those early experiments wouldnt work, said Dick. But lo and behold some of them worked beautifully, and we were able to characterize leukemia stem cells and non-stem cells. Leukemia is a caricature of normal developmentand we exploited that.

Dick and his team began counting individual cells much likeJames TillandErnest McCullochafter their discovery of stem cells in Toronto in 1961, Dick noted. They made the startling finding that stem cells are extremely rare in acute myeloid leukemia roughly one in a million, in a given population of leukemia cells.

They later found that relapse of acute myeloid leukemia is linked to the survival of leukemia stem cells after therapyand, using patient blood samples, they showed that leukemia stem cells that cause relapse are already present in the blood the day the patient first shows up at the clinic and before therapy begins.

Dicks lab eventually developed a 17-gene stemness score that physicians use to predict patient risk and outcomes, which increasingly helps guide therapeutics. Its a new kind of approach for effective patient-specific intervention, which is gratifying, Dick said.

Dick credits many colleagues for his successes, starting with the trainees in his lab. He said their technical skills and passion were critical, andthat their ideas were often essential.

For most of our findings, no one had the right ideas, Dick said. We just threw our thoughts in a melting pot the good and the bad, and the resulting fusion took us in completely unexpected directions. In that intellectual foment, trainees have contributed so much. Theyve been the best post-docs and graduate students you could imagine.

He also thanked his clinical collaborators at Princess Margaret Cancer Centre and other hospitals, as well as his colleagues at U of T.

Human disease is the best sourcebook for raising and testing research questions, so I needed that constant interchange with clinicians, Dick said. But I benefited hugely from the intellectual rigour and collegiality of my colleagues in molecular genetics. I dont think I could have done this work anywhere but Toronto.

Bhuttas career began in neonatology in Pakistan, but he soon expanded his focus beyond infants.

I realized you cant work with babies without working with mothers and the moment you start working with mothers, you get to social determinants of health, said Bhutta, the first U of T faculty member to win the John Dirks Canada Gairdner Global Health Award.

For more than three decades, Bhuttas research has influenced policy and practice in global child and maternal health through implementation science, research synthesis and trials, as well as studies of malnutrition and obesity, among other approaches.

Ive learned as I went along, but Ive been fortunate to work in a variety of areas, often on large-scale projects, with opportunities to make a difference in the short- and long-term, said Bhutta, who is also affiliated with U of Ts Joannah & Brian Lawson Centre for Child Nutrition.

Bhutta and his colleagues at Aga Khan University provided some of the first scientific evidence on the impact of lady health workers in community-based interventions in Pakistan. The government ofBenazir Bhutto began employing the workers in the mid-1990s, with the goal of reducing child and maternal risk factors and deaths.

Bhutta and his team helped evaluate those interventions in a series of cluster randomized trials a method common in public health that allows researchers to compare program impacts across groups or clusters of people. Among their findings: using chlorhexidine for cord care during home births reduced neonatal infection and death and public-sector community health workers working in rural populations could indeed help reduce perinatal fatalities.

They also showed that when women began to visit health facilities, facility-based births increased. Moreover, they found that womens embrace of the community health system did not falter after the formal period of the intervention ended.

Thats diffusion of innovation, when improvements become ingrained, said Bhutta. People said that women would suffer de-development after the initial intervention, but that did not happen. The lesson was that when you increase capacity around womens health, you can move away and they never look back.

Bhutta and his team provided evidence for expansion of the community-based worker model in Pakistan and countries in the Global South, but their work also highlighted the limits of what those workers can achieve.

You cant do much about a woman who is bleeding to death without access to a facility with a blood bank, Bhutta said. Ive seen many efforts to upgrade community interventions to physician-level care fall flatbecause community workers are not physicians.

Many of those failures were closely linked to social determinants of health, Bhutta said. He recalled that in a Pakistani hospital where his wife worked in the 1990s, pregnant women kept arriving dead at the hospitaldespite living just a few kilometres away. It turned out the delays were often due to an imbalance in decision-making power between males in females,a lack of money for transportor misunderstanding of the severity of the medical crisis.

These problems dont have a biomedical solution, said Bhutta. They need education, womens empowerment, and building social and economic resources at the community level.

Today, Bhutta continues to pursue research on child and maternal health in the Global Southand among marginalized populations in high-income countries. But he is broadening his focus further to address another social determinant of health: climate change.

I would like to work on solutions to climate change for the poorest of poor before countries agree and develop policy, said Bhutta. People are dying nowfrom food shortages and heat shocks. I want to help bring communities together on a self-help basisto promote innovations without the need for external supports. Watch that space.

The Gairdner Foundation was established in 1957 to recognize research that impacts human healthand has since given 402 awards to scientists around the world. About a quarter of those researchers later received Nobel Prizes. The foundation gives seven awards annually. Each recipient receives $100,000and participates in public lectures, research symposia and other outreach events. The foundation is supported by the Government of Canada.

View post:
John Dick and Zulfiqar Bhutta win Canada Gairdner Awards - University of Toronto

Posted in Stem Cells | Comments Off on John Dick and Zulfiqar Bhutta win Canada Gairdner Awards – University of Toronto

Skin Closure Systems Market: The skin closure strips segment is likely to register a relatively high growth rate during the forecast period – BioSpace

Posted: April 6, 2022 at 2:04 am

Albany NY, United States: Advanced skin closure systems are rapidly being adopted by patients over the last few years, due to advantages such as minimized scarring and improved tolerance of skin. Technological advancements in the adhesive used in skin closure systems have led to improved healing, as these products do not traumatize the edges of surgery site or wound and provide pain-free closure.

Read Report Overview - https://www.transparencymarketresearch.com/skin-closure-systems-market.html

Growing rates of incidence of chronic wounds, rising preference by surgeons for improving patients quality of life, strong emergence of local companies offering skin closure systems at relatively low average selling prices (thereby resulting in reduction in exports and expansion of the domestic market for skin closure systems), and increasing focus by manufacturers on the development of innovative products to reduce the cost burden of post-operative care are some of the factors projected to drive the global skin closure systems market during the forecast period. However, availability of alternative advanced devices for skin closure and increasing pricing pressure in the low-value disposable product segment led by the fragmented market scenario are likely to restrain the global skin closure systems market from 2018 to 2026.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45132

The global skin closure systems market can be segmented based on product, application, treatment, end-user, and region. In terms of product, the global skin closure systems market can be classified into skin closure strips, sutures & staples, glues, and others. The sutures & staples segment can be sub-divided into sterile and non-sterile. The skin closure strips segment is likely to register a relatively high growth rate during the forecast period, owing to increasing approvals for technologically advanced products that promote non-invasive skin closure. For instance, ZipLine Medical, Inc. announced to have received approval from China Food & Drug Administration (CFDA) for its non-invasive surgical skin closure systems in May 2017. In terms of application, the global skin closure systems market can be bifurcated into invasive skin closure systems and non-invasive skin closure systems. Based on treatment, the market can be divided into surgical skin closure and wound closure. The surgical skin closure segment has been sub-categorized into general surgery, orthopedic surgery, gynecological surgery, cosmetic surgery, and others. Based on end-user, the global skin closure systems market has been classified into long-term care centers, home use, hospitals, clinics, skilled nursing facilities, ambulatory surgical centers, and others. The hospitals segment is projected to dominate the market, in terms of value, from 2018 to 2026, owing to significant improvements in the healthcare infrastructure in developing countries with high growth potential such as China.

Request for Analysis of COVID-19 Impact on Skin Closure Systems Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=45132

Geographically, the global skin closure systems market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in Asia Pacific is projected to register an above-average growth rate, in terms of value, between 2018 and 2026. This is attributable to significant patient pool suffering from lifestyle-associated disorders such as diabetes and obesity, rise in the demand for affordable and advanced care in the region, and growing inclination of physicians toward adoption of advanced non-invasive skin closure systems in post-surgical and wound care. The skin closure systems market in North America and Europe is developed. The two regions are estimated to hold significant market shares throughout the forecast period, due to increasing focus of major market players to enter the market in these regions. This can be attributed to established reimbursement policies and strong presence of established companies with proper distribution networks in these regions.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=45132

Prominent players operating in the global skin closure systems market are 3M, BSN medical, Chemence Medical, Inc., Ethicon, Inc. (Johnson & Johnson), ZipLine Medical, Inc., Cellpoint Scientific Inc., Smith & Nephew, MicroMend, and Medline Industries Inc.

Pre Book Skin Closure Systems Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=45132&ltype=S

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

More Trending Reports by Transparency Market Research:

Digital Pregnancy Test Kits Market Pregnancy test is an indicative marker test for determination of pregnancy, which measures the human chorionic gonadotropin (HCG) in urine samples. The HCG hormone is present in the human body only during pregnancy, which makes it possible for the test to provide accurate results. Various types of pregnancy tests are available in the market. Home pregnancy test (HPT) is the most common, which offers benefits of pregnancy testing at home, without the need to visit a physician or gynecologist.

Stem Cell Banking Market Stem cell banking is the practice of preserving blood cell from a newborn baby for future use. The preserved blood is used in medical therapies for various diseases, such as sarcoma, leukemia, immune conditions, lymphoma, and metabolic disorders. Stem cells are capable of producing blood cells such as red blood cells, platelets, and white blood cells, which are produced in the human body.

Laboratory Informatics Market Laboratory informatics is defined as a specialized application of information technology to optimize and extend laboratory operations through a platform of instruments, software, and data management tools. This allows scientific data to be captured, migrated, processed, and interpreted for immediate use, as well as stored, managed, and shared to support future research, development, and lab testing efforts, while maximizing the efficiency of laboratory operations. Laboratory informatics is one of the fastest growing areas of laboratory-related technology.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Original post:
Skin Closure Systems Market: The skin closure strips segment is likely to register a relatively high growth rate during the forecast period - BioSpace

Posted in Stem Cells | Comments Off on Skin Closure Systems Market: The skin closure strips segment is likely to register a relatively high growth rate during the forecast period – BioSpace

World’s Third AIDS Patient Cured – WESTVIEW NEWS – WestView News

Posted: April 6, 2022 at 2:04 am

What Does it Mean for a Global Cure?

By Kambiz Shekdar, Ph.D.

Within the research community, the Holy Grail to cure AIDS had been to find new drugs to Shock and Kill the festering virus from its hiding places (latent infections and viral reservoirs). No such drugs have been developed, yet three persons have been cured using highly imaginative stem cell strategies. The most recent stem cell cure reported in February 2022 is beginning to cause the field to re-think and expand strategies to develop a global cure, including new initiatives by NIH.

HIV INFECTION. The goal of a cure for HIV is to replace human T-cells infected with HIV (left) with non-infected cells (right). Photo credit: Nancy Burson in collaboration with Kunio Nagashima.

Many readers of this newspaper will remember the height of the AIDS epidemic. New York Citys West Village, where this newspaper is based, has always been one of the epicenters of the AIDS epidemic in the United States. The neighborhoods St. Vincents Hospital, now closed, once served as the center for compassionate care of dying patients. Today, an AIDS Memorial sits adjacent to where St. Vincents once stood, as though AIDS is history. In fact, the best way we can memorialize those lost to AIDS and impact the lives and health of future generations to come all around the world is to build a research incubator and hub to accelerate a global cure, right here in New York City.

A brief timeline of 40 years of AIDS: the modern HIV epidemic started in the early 1980s. The first life-saving AIDS drug cocktail was introduced by Dr. David Ho in 1995. Global access to the drugs was initiated by President George W. Bush in 2003 via PEPFAR (Presidents Emergency Plan for AIDS Relief). In 2012, the FDA approved the use of existing AIDS medications to prevent HIV infection. AIDS may have been tamed, but it did not go away; it has been smoldering ever since.

HIV-associated neurocognitive disorders (HAND) occur in some 50% of people living with HIV. HAND is not in the least bit addressable by any of the many existing AIDS medications available today, not even in people who may achieve undetectable viral levels using existing AIDS medications. The disease continues to ravish the poorest and most disenfranchised communities, in the U.S. this started with the gays and now includes black women, our prison populations, trans individuals and our inner cities.

40 million people around the world are living with HIV, making Planet Earth a massive petri dish for the emergence of new strains. COVIDs Delta, Omicron, and Deltacron variants illustrate how infectious agents can change and evade existing defenses. So far, drug makers have been able to develop stronger and newer drugs to new strains of HIV, but this is getting more challenging all the time. Moreover, young gay men in the U.S. have largely stopped using condoms, creating ideal conditions for the spread of any drug-resistant HIV.

With treatment and prevention drugs alone, we can maintain a smoldering HIV/AIDS epidemic, but we cannot end it. With a cure, a vaccine or both, we can end AIDS for good and wipe HIV off the face of the planet.

ENTER CURE: Timothy Ray Brown is the first person cured of AIDS. Mr. Brown recounted how he was cured at a symposium at Columbia University organized by Research Foundation to Cure AIDS. He said that he suffered from both leukemia and AIDS. His physician, Dr. Gero Hutter, had an idea. Dr. Hutter was not an HIV or AIDS specialist, but he recalled from his days in medical school how certain rare individuals are naturally resistant to HIV/AIDS. Mr. Brown needed a bone marrow stem cell transplant to cure his leukemia. What if, Dr. Hutter reasoned, the stem cell transplant was sourced from a donor who is selected from the group of individuals who is naturally resistant to HIV. Could the transplanted stem cells give rise to a new HIV-resistant immune system that would cure Mr. Brown of both AIDS and leukemia? Mr. Brown was a willing guinea pig. The answer to this pairs experiment was a resounding YES!

Who was this leukemia doctor with claims of using stem cells to cure AIDS in 2007, when stem cell science was new and when almost all the experts in the field believed new drugs, not stem cells, were required to achieve a cure? Not even long-time AIDS activists popped any champagne bottles. Was this yet another case of drinking goats milk to cure AIDS? It took years for news of the innovative cure to catch.

DRIP BY MONUMENTAL DRIP, the three cures to date and the new knowledge gleaned from each success have chipped away at the calcified and crusty assumptions with the real-world data and results of what works to cure AIDS. Each of the cures and their contribution to the field of curing AIDS using innovative stem cell strategies are summarized below.

STEM CELL CURE #1, reported in 2007, used HIV resistant stem cells to cure AIDS. But because only one person was cured, it was formally possible that something else or extra about the biology or genetics of either the donor or the patient, or both, was at play. In addition, because the patient suffered from leukemia as well as AIDS, he underwent radiation to eliminate his cancerous immune system first. Also, the donor-derived stem cells that were transplanted into the patient caused a phenomenon known as GVHD (graft versus host disease) where the implanted cells attacked the recipients own cells. Any of these factors could have contributed to the cure of the patient in addition to the curative role of the HIV-resistant stem cell transplant.

STEM CELL CURE #2, reported in 2019, was achieved in much the same way as the first. Now two people were cured, not just one, providing clinical proof that the cure could be repeated and that the first case was not a fluke. Also, by this time, similar cures were attempted in additional patients who suffered with both leukemia and AIDS but using regular stem cell transplants and not HIV-resistant stem cells. All these attempted cures failed, suggesting that radiation to kill off a patients cancerous immune system without adding back HIV resistant stem cells is not sufficient to cure AIDS.

STEM CELL CURE #3, reported in 2022, makes a compelling trifecta. This third was achieved in a multiracial woman. With the first cure being that of a White man, the second that of a Latino male, and the third a multiracial woman, together, the diverse backgrounds of the three individuals cured to date dispels the possibility that any particular biology or genetics of the individuals involved was likely a key factor in achieving any of these cures. Moreover, GVHD did not take hold in patient #3, increasingly pointing to a central curative role being played by the naturally HIV resistant stem cells that were in common across all three cures to date.

Any time when the first patients are cured from a disease that has been lingering for decades, the primary goal of the research community must be to investigate all possible factors, especially all of the factors that were involved in the index cases, that could have contributed to the outcome. 15 years ago, Dr. Hutter showed us all a cure is possible. It took the NIH until the end of 2019 to make its first major announcement prioritizing the development of a global cure for AIDS. Regrettably, the COVID pandemic hit just six weeks later. Since then, I have seen one narrowly-defined call from the NIH for research proposals expressly focused on curing AIDS.

Much more can and must be done to make up for lost time and mobilize a cure. During the last 40 years of living with AIDS, the focus has been on drugs to treat and prevent HIV/AIDS. Now, the cure of three patients using stem cells points to the need to invigorate and add to the field. Room must be made to add new teams that bring novel and differentiated cellular biotechnologies needed to harness natural and curative biological resistance to HIV to develop a global cure.

For full disclosure, I am President and Founder of Research Foundation to Cure AIDS (RFTCA). RFTCA is not about treatment or prevention; were about the cure. Together with our collaboration partners at Columbia University Medical Center, New York Stem Cell Foundation, New York Blood Center and others, RFTCA has applied for NIH grant funding to advance innovate stem cell science originating from The Rockefeller University.

The imaginative and breathtaking results that Dr. Hutter demonstrated when he combined pieces of knowledge known to allbut synthesized by none before himinto a coherent sequence of events that cured AIDS for the first time ever, inspired me ever since I heard about his work. The recent news of the third patient cured of AIDS and how this cure specifically informs the field makes me more hopeful than ever about the prospects of developing a global cure.

Rockefeller University alumnus and biotech inventor Kambiz Shekdar, Ph.D., is the president of Research Foundation to Cure AIDS and Science & LGBTQ editor at WestView News. To support RFTCA, go to https://rftca.org/.

Original post:
World's Third AIDS Patient Cured - WESTVIEW NEWS - WestView News

Posted in Stem Cells | Comments Off on World’s Third AIDS Patient Cured – WESTVIEW NEWS – WestView News

Meatable CEO weighs into debate over viability of cell-cultured meat: ‘What matters is the biomass accumulation rate’ – FoodNavigator-USA.com

Posted: April 6, 2022 at 2:04 am

I want to make sure that by 2025, we have a cost competitive product on the market [on parity with] organic [meat] and we feel very comfortable that we can get there, said Krijn de Nood, who was speaking to FoodNavigator-USA about the ongoing debate over the commercial viability of growing meat from animal cells, at scale, outside of an animal, a technology Impossible Foods founder Dr Pat Brown has dismissed as vaporware.

Asked about last years article in The Counter (drawing upon two techno-economic analyses of cell-cultured meat: CE Delft 2021 andHumbird 2020) arguing that cell-cultured meat faces "intractable technical challenges at food scale, de Nood said: Its always good to read those articles and test your hypotheses and see if you are wrong.

But if we look at our models, both on the scalability trajectory and on the cost reduction trajectory, we feel very comfortable that by 2025, we can go to the market with a price competitive product. The Delft analysis assumed 32 days for the whole process and we can do it - proliferating the cells and then [differentiating] them into muscle and fat cells in less than two weeks.

This also gives us a huge cost advantage from an energy and labor perspective.

While achieving certain cell densities is important, he said, What matters is the biomass accumulation rate. Maybe you can have great cell densities, but if it takes you six weeks to get to them, thats not so efficient, so its one of the reasons we chose iPScs [induced pluripotent stem cells], because they have a faster proliferation rate, they divide faster, so the accumulation of kilograms of meat is faster.

Obviously there's a risk accompanied with scaling up any process, but were not talking about a wild gamble here.

Meatable - which is working with porcine and bovine induced pluripotent stem cells - closed a $47m Series A round (bringing its total funding to $60m) last year, and has just hired former Chr. Hansen president and CEO Cees de Jong as chairman of the board; former Fonterra Europe & Africa president Hans Huistra as COO; and biochemist Jef Pinxteren as VP of development.

At our[pilot-scale]production facility in Delft, we have moved from grams to the kilograms range, so product development can take a big leap, plus for regulatory approval you also need to produce consistent batches, said de Nood.

We have gone from being an R&D company to being a food company.

For commercial launch, he said, Singapore[where cell-cultured meat products, from Eat Just, are already on sale, albeit on a tiny scale]is probably going to be an interesting entry market. After that, we hope that the US will open up for us, as from a market size perspective, its a much more attractive proposition than Singapore, although Singapore is a very good testing market as there are people with a lot of different ethnicities and a willingness to adopt new technologies.

Currently, Meatable is considering asemi-commercialfacility in Singapore, while a larger-scale facility capable of producing 10 kilotons a year would probably be better placed in a larger market such as the US or Europe.

In Europe, said de Nood,the positive thing is that the regulatory landscape is defined[firms must go through the Novel Food Regulation, a pre-market approval process],but it takes a long time, whereas in the US, the process is a work in progress [the FDA says it will publish draft guidance on the pre-market consultation process this year], but seems likely to move more rapidly, he said. "Hopefully months not years.

Meatables first commercial product will be pork, said de Nood. Pork is the most consumed meat globally, especially in Asia, plus there's also a supply demand imbalance right now because of swine fever. But we have also developed a beef line, which is super interesting, especially for Europe and the US our technology is species independent, so at some point we will dofish as well."

He added: Right now what we believe we need for commercial scale is about 10,000 liter bioreactors, but thats only at the beginning, and thats why its so special we have a collaboration with DSM, as they have experience of working with bioreactors on a large scale. DSM also has a lot of experience with taste and texture enhancers[that Meatable can tap into].

Asked about progress on enabling technologies for cell-cultured meat, de Nood said: If you just look at all the growth factors, the amino acids, the minerals that are required, what is very encouraging is that not only startups, but also big corporates are jumping into this, so we have a joint development agreement with DSM, which is really focused on reducing the cost of growth factors[produced via microbial fermentation].

There are several things we can do, so one is moving from pharma to food grade, one is finding other microorganisms to produce these growth factors, and there's also adaptation of the cells so they actually need less. There are a lot of opportunities to really get costs down quite significantly.

So what kinds of products is Meatable working on?

For the first products,said de Nood,we have the two [separate]production lines[for fat and muscle cells]and then we mix them at the end, but we are also working on whole cuts, which account for a huge percentage of the[conventional meat]market, and we are one of the few companies who can actually co-culture cells, so that's exciting stuff.

Asked about scaffolding, he said,We're using a variety of different scaffolds, but its a little bit IP sensitive.

Meatable is effectively reprogramming Hematopoietic stem cells (HSCs) so that they turn into [induced] pluripotent stem cells (iPS cells) or master cells that can differentiate into multiple cells types such as muscle and fat, and proliferate indefinitely.

Induced pluripotent stem cells behave like embryonic stem cells, but dont come from embryos, and dont require the slaughter or harm of any animal, CTO Dan Luining told us when the company emerged from stealth mode in 2018:"The collection method is truly non-invasive. After the calf is born and the umbilical cord is detached, we cannulate one of the veins in the cord and collect the blood in a blood bag. From this blood we isolate cells in the lab."

After that, the blood cells are effectively 'reprogrammed' to a pluripotent state using technologypioneered by Shinya Yamanakas lab in Kyoto, Japan that was awarded the2012 Nobel prize.

Luining added:"The method works by temporarily kickstarting the genes that were active during the state when the animal was only a few cells big. At that moment the cells were in a stage where they could become anything, which we call pluripotent. Professor Yamanaka figured out which genes were active at that time and showed that if you kickstart these genes again the cells behave like pluripotent cells.

"Once started the pluripotent state becomes stable and the cells self-perpetuate this state. These cells have amazing benefits including: unlimited proliferation, complete serum free growth, suspension growth, and pluripotency, the ability to become any cell type that we want.

See the article here:
Meatable CEO weighs into debate over viability of cell-cultured meat: 'What matters is the biomass accumulation rate' - FoodNavigator-USA.com

Posted in Stem Cells | Comments Off on Meatable CEO weighs into debate over viability of cell-cultured meat: ‘What matters is the biomass accumulation rate’ – FoodNavigator-USA.com

Single-cell RNA sequencing analysis of human bone-marrow-derived mesenchymal stem cells and functional subpopulation identification – DocWire News

Posted: April 6, 2022 at 2:04 am

This article was originally published here

Exp Mol Med. 2022 Apr 1. doi: 10.1038/s12276-022-00749-5. Online ahead of print.

ABSTRACT

Mesenchymal stem cells (MSCs) are a common kind of multipotent cell in vivo, but their heterogeneity limits their further applications. To identify MSC subpopulations and clarify their relationships, we performed cell mapping of bone-marrow-derived MSCs through single-cell RNA (scRNA) sequencing. In our study, three main subpopulations, namely, the stemness subpopulation, functional subpopulation, and proliferative subpopulation, were identified using marker genes and further bioinformatic analyses. Developmental trajectory analysis showed that the stemness subpopulation was the root and then became either the functional subpopulation or the proliferative subpopulation. The functional subpopulation showed stronger immunoregulatory and osteogenic differentiation abilities but lower proliferation and adipogenic differentiation. MSCs at different passages or isolated from different donors exhibited distinct cell mapping profiles, which accounted for their corresponding different functions. This study provides new insight into the biological features and clinical use of MSCs at the single-cell level, which may contribute to expanding their application in the clinic.

PMID:35365767 | DOI:10.1038/s12276-022-00749-5

Here is the original post:
Single-cell RNA sequencing analysis of human bone-marrow-derived mesenchymal stem cells and functional subpopulation identification - DocWire News

Posted in Stem Cells | Comments Off on Single-cell RNA sequencing analysis of human bone-marrow-derived mesenchymal stem cells and functional subpopulation identification – DocWire News

We finally have a fully complete human genome – Science News Magazine

Posted: April 6, 2022 at 2:01 am

Researchers have finally deciphered a complete human genetic instruction book from cover to cover.

The completion of the human genome has been announced a couple of times in the past, but those were actually incomplete drafts. We really mean it this time, says Evan Eichler, a human geneticist and Howard Hughes Medical Institute investigator at the University of Washington in Seattle.

The completed genome is presented in a series of papers published online March 31 in Science and Nature Methods.

An international team of researchers, including Eichler, used new DNA sequencing technology to untangle repetitive stretches of DNA that were redacted from an earlier version of the genome, widely used as a reference for guiding biomedical research.

Deciphering those tricky stretches adds about 200 million DNA bases, about 8 percent of the genome, to the instruction book, researchers report in Science. Thats essentially an entire chapter. And its a juicy one, containing the first-ever looks at the short arms of some chromosomes, long-lost genes and important parts of chromosomes called centromeres where machinery responsible for divvying up DNA grips the chromosome.

Some of the regions that were missing actually turn out to be the most interesting, says Rajiv McCoy, a human geneticist at Johns Hopkins University, who was part of the team known as the Telomere-to-Telomere (T2T) Consortium assembling the complete genome. Its exciting because we get to take the first look inside these regions and see what we can find. Telomeres are repetitive stretches of DNA found at the ends of chromosomes. Like aglets on shoelaces, they may help keep chromosomes from unraveling.

Data from the effort are already available for other researchers to explore. And some, like geneticist Ting Wang of Washington University School of Medicine in St. Louis, have already delved in. Having a complete genome reference definitely improves biomedical studies. Its an extremely useful resource, he says. Theres no question that this is an important achievement.

But, Wang says, the human genome isnt quite complete yet.

To understand why and what this new volume of the human genetic encyclopedia tells us, heres a closer look at the milestone.

Headlines and summaries of the latest Science News articles, delivered to your inbox

Thank you for signing up!

There was a problem signing you up.

Eichler is careful to point out that this is the completion of a human genome. There is no such thing as the human genome. Any two people will have large portions of their genomes that range from very similar to virtually identical and smaller portions that are wildly different. A reference genome can help researchers see where people differ, which can point to genes that may be involved in diseases. Having a view of the entire genome, with no gaps or hidden DNA, may give scientists a better understanding of human health, disease and evolution.

The newly complete genome doesnt have gaps like the previous human reference genome. But it still has limitations, Wang says. The old reference genome is a conglomerate of more than 60 peoples DNA (SN: 3/4/21). Not a single individual, or single cell on this planet, has that genome. That goes for the new, complete genome, too. Its a quote-unquote fake genome, says Wang, who was not involved with the project.

The new genome doesnt come from a person either. Its the genome of a complete hydatidiform mole, a sort of tumor that arises when a sperm fertilizes an empty egg and the fathers chromosomes are duplicated. The researchers chose to decipher the complete genome from a cell line called CHM13 made from one of these unusual tumors.

That decision was made for a technical reason, says geneticist Karen Miga of the University of California, Santa Cruz. Usually, people get one set of chromosomes from their mother and another set from their father. So we all have two genomes in every cell.

If putting together a genome is like assembling a puzzle, you essentially have two puzzles in the same box that look very similar to each other, says Miga, borrowing an analogy from a colleague. Researchers would have to sort the two puzzles before piecing them together. Genomes from hydatidiform moles dont present that same challenge. Its just one puzzle in the box.

The researchers did have to add the Y chromosome from another person, because the sperm that created the hydatidiform mole carried an X chromosome.

Even putting one puzzle together is a Herculean task. But new technologies that allow researchers to put DNA bases represented by the letters A, T, C and G in order, can spit out stretches up to more than 100,000 bases long. Just as childrens puzzles are easier to solve because of larger and fewer pieces, these long reads made assembling the bits of the genome easier, especially in repetitive parts where just a few bases might distinguish one copy from another. The bigger pieces also allowed researchers to correct some mistakes in the old reference genome.

For starters, the newly deciphered DNA contains the short arms of chromosomes 13, 14, 15, 21 and 22. These acrocentric chromosomes dont resemble nice, neat Xs the way the rest of the chromosomes do. Instead, they have a set of long arms and one of nubby short arms.

The length of the short arms belies their importance. These arms are home to rDNA genes, which encode rRNAs, which are key components of complex molecular machines called ribosomes. Ribosomes read genetic instructions and build all the proteins needed to make cells and bodies work. There are hundreds of copies of these rDNA regions in every persons genome, an average of 315, but some people have more and some fewer. Theyre important for making sure cells have protein-building factories at the ready.

We didnt know what to expect in these regions, Miga says. We found that every acrocentric chromosome, and every rDNA on that acrocentric chromosome, had variants, changes to the repeat unit that was private to that particular chromosome.

By using fluorescent tags, Eichler and colleagues discovered that repetitive DNA next to the rDNA regions and perhaps the rDNA too sometimes switches places to land on another chromosome, the team reports in Science. Its like musical chairs, he says. Why and how that happens is still a mystery.

The complete genome also contains 3,604 genes, including 140 that encode proteins, that werent present in the old, incomplete genome. Many of those genes are slightly different copies of previously known genes, including some that have been implicated in brain evolution and development, autism, immune responses, cancer and cardiovascular disease. Having a map of where all these genes lie may lead to a better understanding of what they do, and perhaps even of what makes humans human.

One of the biggest finds may be the structure of all of the human centromeres. Centromeres, the pinched portions which give most chromosomes their characteristic X shape, are the assembly points for kinetochores, the cellular machinery that divvies up DNA during cell division. Thats one of the most important jobs in a cell. When it goes wrong, birth defects, cancer or death can result. Researchers had already deciphered the centromeres of fruit flies and the human 8, X and Y chromosomes (SN: 5/17/19), but this is the first time that researchers got a glimpse of the rest of the human centromeres.

The structures are mostly head-to-tail repeats of about 171 base pairs of DNA known as alpha satellites. But those repeats are nestled within other repeats, creating complex patterns that distinguish each chromosomes individual centromere, Miga and colleagues describe in Science. Knowing the structures will help researchers learn more about how chromosomes are divvied up and what sometimes throws off the process.

Researchers also now have a more complete map of epigenetic marks chemical tags on DNA or associated proteins that may change how genes are regulated. One type of epigenetic mark, known as DNA methylation, is fairly abundant across the centromeres, except for one spot in each chromosome called the centromeric dip region, Winston Timp, a biomedical engineer at Johns Hopkins University and colleagues report in Science.

Those dips are where kinetochores grab the DNA, the researchers discovered. But its not yet clear whether the dip in methylation causes the cellular machinery to assemble in that spot or if assembly of the machinery leads to lower levels of methylation.

Examining DNA methylation patterns in multiple peoples DNA and comparing them with the new reference revealed that the dips occur at different spots in each persons centromeres, though the consequences of that arent known.

About half of genes implicated in the evolution of humans large, wrinkly brains are found in multiple copies in the newly uncovered repetitive parts of the genome (SN: 2/26/15). Overlaying the epigenetic maps on the reference allowed researchers to figure out which of many copies of those genes were turned on and off, says Ariel Gershman, a geneticist at Johns Hopkins University School of Medicine.

That gives us a little bit more insight into which of them are actually important and playing a functional role in the development of the human brain, Gershman says. That was exciting for us, because theres never been a reference that was accurate enough in these [repetitive] regions to tell which gene was which, and which ones are turned on or off.

One criticism of genetics research is that it has relied too heavily on DNA from people of European descent. CHM13 also has European heritage. But researchers have used the new reference to discover new patterns of genetic diversity. Using DNA data collected from thousands of people of diverse backgrounds who participated in earlier research projects compared with the T2T reference, researchers more easily and accurately found places where people differ, McCoy and colleagues report in Science.

The Telomere-to-Telomere Consortium has now teamed up with Wang and his colleagues to make complete genomes of 350 people from diverse backgrounds (SN: 2/22/21). That effort, known as the pangenome project, is poised to reveal some of its first findings later this year, Wang says.

McCoy and Timp say that it may take some time, but eventually, researchers may switch from using the old reference genome to the more complete and accurate T2T reference. Its like upgrading to a new version of software, Timp says. Not everyone is going to want to do it right away.

The completed human genome will also be useful for researchers studying other organisms, says Amanda Larracuente, an evolutionary geneticist at the University of Rochester in New York who was not involved in the project. What Im excited about is the techniques and tools this team has developed, and being able to apply those to study other species.

Eichler and others already have plans to make complete genomes of chimpanzees, bonobos and other great apes to learn more about how humans evolved differently than apes did. No one should see this as the end, Eichler says, but a transformation, not only for genomic research but for clinical medicine, though that will take years to achieve.

Scientists and journalists share a core belief in questioning, observing and verifying to reach the truth. Science News reports on crucial research and discovery across science disciplines. We need your financial support to make it happen every contribution makes a difference.

Originally posted here:
We finally have a fully complete human genome - Science News Magazine

Posted in Human Genetics | Comments Off on We finally have a fully complete human genome – Science News Magazine

Researchers identify regions of genome involved in Alzheimer’s – UPI News

Posted: April 6, 2022 at 2:01 am

New research has identified 75 regions of the human genome involved in Alzheimer's development. File photo by BillionPhotos.com/Shutterstock

April 4 (UPI) -- An international team of researchers has identified 75 regions of the human genome associated with the development of Alzheimer's disease, including 42 never before linked with the common form of dementia, they said Monday.

After analyzing the genomes, or complete genetic data, for thousands of people, the researchers found 75 loci, or regions, of DNA involved in Alzheimer's, they reported in an article published Monday by the journal Nature Genetics.

Several of the identified regions of the genome are involved in the accumulation of amyloid-beta in the brain, which is known to cause Alzheimer's, according to the researchers.

In addition, they identified genes that affect production of a protein called tau that is found in brain cells. Changes in tau production also have been linked with Alzheimer's disease, the researchers said.

Based on their findings, the researchers have developed a genetic "risk score" for Alzheimer's, though it is still in the draft stage and is not yet ready for use in clinical practice, they said.

"Our knowledge of the genetics of AD common forms cannot allow it to be used as an individual diagnostic tool yet," study co-author Jean-Charles Lambert told UPI in an email.

"On the other hand, we show in our paper that this knowledge makes it possible in populations to define groups of individuals more or less at risk of developing the [disease]," said Lambert, research director at Inserm in Lille, France.

On Thursday, researchers working with the National Human Genome Research Institute announced that they had mapped a complete human genome for the first time.

This map could serve as a "reference," or guide, for researchers seeking to identify the genetic component of various diseases and traits, they said.

Amyloid-beta and tau have both been linked with Alzheimer's, the most common form of dementia in the United States, affecting some 6 million people, most of whom are age 65 years and older, according to the Alzheimer's Association.

However, it is not yet fully understood why some people have higher levels of amyloid-beta in their brains than others, placing them at higher risk for cognitive, or brain function, decline, Lambert said.

Most cases of Alzheimer's are thought to be caused by the interaction of different genetic and environmental factors, the latter of which include air pollution, research suggests.

In addition to identifying the genome regions behind amyloid-beta and tau development, Lambert and his colleagues also noted that many people with Alzheimer's also have modifications, or changes, in the genome that impact immune response, they said.

These changes affect the function of microglia, or the immune cells in the central nervous system that play a "trash collector" role by eliminating toxic substances, the researchers said.

The analysis also revealed that the tumor necrosis factor alpha-dependent signaling pathway, which plays a role in cell development, according to researchers.

The findings suggest that future clinical trials of therapies designed to treat Alzheimer's should focus on targeting amyloid-beta, microglial cells and the tumor necrosis factor alpha signaling pathway, they said.

They plan to validate the accuracy of their genetic risk score in future studies.

"This genetic knowledge will be the basis of personalized medicine" for Alzheimer's patients, Lambert said.

"This research is important today for the development of therapeutic approaches but in the not-so-distant future, for the clinical management of patients at the earliest stage," he said.

Here is the original post:
Researchers identify regions of genome involved in Alzheimer's - UPI News

Posted in Human Genetics | Comments Off on Researchers identify regions of genome involved in Alzheimer’s – UPI News

Phase 1 Trial Begins Dosing of TARA-002 Cell Therapy for NMIBC – Targeted Oncology

Posted: April 6, 2022 at 2:00 am

The phase 1 ADVANCED-1 trial of the biologic immunopotentiator agent TARA-002 began dosing patients with non-muscular invasive bladder cancer.

A clinical trial investigating the safety and toxicity of TARA-002, a cell therapy agent, for non-muscular invasive bladder cancer (NMIBC), has started dosing, according to a press release from Protara Therapeutics.1

The new immunopotentiator agent phase 1 ADVANCED-1 trial (NCT05085977) is now investigating a single-arm, open-label, dose-finding trial of TARA-002 for treatment-naive and previously treated patients with NMIBC with high-grade carcinoma in situ (CIS) and high-grade papillary tumors.

NMIBC is one of the most recurrent and difficult to treat cancers with very limited treatment options, Jesse Shefferman, chief executive officer of Protara Therapeutics, said in a statement. We are thrilled to have dosed the first patient in our phase 1 study in NMIBC and look forward to exploring TARA-002s full potential in this pressing area of high unmet need.

TARA-002 is an immunopotentiator cell therapy based on group A Streptococcus pyogenes that cause immune cells to produce a local inflammatory cytokine reaction that destroys abnormal cells in a cyst or tumor. It was developed from the same genetic cell bank as OK-432 (Picibanil), a broad immunopotentiator that is approved in Japan and Taiwan.

The phase 1a of the ADVANCED-1 trial is enrolling an estimated 18 patients with NMIBC to receive 6 weekly intravesical doses of TARA-002. Patients are eligible if they are unable to receive intravesical Bacillus Calmette-Gurin (BCG), have received at least 1 dose of BCG, or have received at least 1 dose of intravesical chemotherapy.

Patients will receive up to 3 dose levels: 10 KE, 20 KE, and 40 KE, which will be tested sequentially starting with the lowest dose. The goal of the study is to determine the agents safety and tolerability as well as observe for preliminary signs of antitumor activity. The primary end points for the dose escalation phase are dose-limiting toxicities, maximum tolerated dose, and recommended phase 2 dose (RP2D).

The phase 1b dose expansion part of the trial (NCT05085990) is planned to enroll patients with CIS NMIBC in 2023 to receive 6 weekly doses of the RP2D. Its primary end point is the incidence of adverse events in these patients.

In 2021, TARA-002 was granted a rare prediatric disease designation by the FDA for lymphatic malformations, a rare condition affecting young children.2 Protara stated its intention to begin a clinical trial of TARA-002 in a clinical trial in this setting. While OK-432 is the standard-of-care agent to treat lymphatic malformations in Japan and Taiwan, there is no FDA-approved agent for this disease.

While bladder cancer is the 6th most common cancer in the United States today, with NMIBC representing approximately 80% of diagnoses, treatment options for these patients remain limited, Edward M. Messing, MD, a principal investigator of the ADVANCED-1 study and a professor of urology, oncology, and pathology at the University of Rochester said in a statement.1 There is an urgent need for new therapeutic interventions for these patients, as there continues to be an increase in recurrence, progression and an escalated number of patients needing cystectomies.

References:

1. Protara Therapeutics doses first patient in ADVANCED-1 phase 1 study of TARA-002 in non-muscle invasive bladder cancer. Protara Therapeutics. March 24, 2022. Accessed April 1, 2022. https://bit.ly/376E9TY

2. Protara Therapeutics provides regulatory update for TARA-002 for the treatment of lymphatic malformations. Protara Therapeutics. April 23, 2021. Accessed April 1, 2022. https://bit.ly/37cE5lG

See more here:
Phase 1 Trial Begins Dosing of TARA-002 Cell Therapy for NMIBC - Targeted Oncology

Posted in Cell Therapy | Comments Off on Phase 1 Trial Begins Dosing of TARA-002 Cell Therapy for NMIBC – Targeted Oncology

UAB has been recognized as a Program of Experience for CAR-T therapy – University of Alabama at Birmingham

Posted: April 6, 2022 at 2:00 am

UAB has been awarded for its superior CAR-T therapy program services and leadership.

UAB has been awarded for its superior CAR-T therapy program services and leadership. Photography: Steve WoodThe University of Alabama at Birmingham has been identified by Emerging Therapy Solutions as a Program of Experience for Chimeric antigen receptor T cell therapy.

According to the American Cancer Society, CAR-T therapy is a path for immune cells called T cells a type of white blood cell to fight cancer by changing them in the lab so they can find and destroy cancer cells. This form of treatment can be helpful for patients with various cancer types even when other types of treatments are no longer available.

CAR-T therapy is becoming an essential pillar of cancer care, joining the ranks of surgery, chemotherapy, radiation and other targeted treatments.

The UAB-BMT and Cell Therapy Program is the only state-of-the-art program in Alabama to offer CAR-T therapy for patients with some cancers, said Amitkumar Mehta, M.D., associate scientist in the ONeal Comprehensive Cancer Center at UAB, assistant professor in the UAB Division of Hematology and Oncology, Director of CAR-T Program and Medical Director of Clinical Trial Office. The program is certified for all commercial FDA-approved CAR-T products. The program also supports next generation cell therapy treatment through clinical trials. The CAR-T team is a highly specialized and experienced team that supports the patients who are on this treatment. This recognition is an appreciation of the dedicated and patient-centered cell therapy team at UAB-BMT. I am very proud to be part of the program.

ETS created this designation after evaluating centers across the United States that provide CAR-T services and identifying the leading CAR-T programs with the essential experience and resources, including volume of CAR-Ts administered.

Read the original post:
UAB has been recognized as a Program of Experience for CAR-T therapy - University of Alabama at Birmingham

Posted in Cell Therapy | Comments Off on UAB has been recognized as a Program of Experience for CAR-T therapy – University of Alabama at Birmingham

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid…

Posted: April 6, 2022 at 2:00 am

SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and the lead candidate in its cellular therapy portfolio. The trial is designed to evaluate the safety and efficacy of DeTIL-0255 in patients with advanced gynecological malignancies including ovarian cancer, cervical cancer, and endometrial cancer.

DeTIL-0255 is a cell therapy derived via ex-vivo treatment of patient-derived tumor infiltrating lymphocytes (TILs) with a potent, small-molecule inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) called NX-0255, which was identified using Nurixs proprietary DELigase platform.

The initiation of our first cell therapy study is a major milestone for Nurix and the culmination of significant efforts across our clinical, regulatory and manufacturing teams. It is also the first time targeted protein modulation has been combined with cell therapy, marking the beginning of what we believe will be an important step forward in the treatment of solid tumors, said Robert J. Brown, M.D., executive vice president of clinical development of Nurix. Within the rubric of targeted protein modulation, Nurix has now moved three treatment modalities into the clinic including oral targeted protein degraders, an oral CBL-B inhibitor, and now a drug-enhanced cell therapy.

CBL-B is an E3 ligase that is expressed in immune cells, and in the context of cancer functions as an intracellular checkpoint that negatively regulates T cell activation, NK cell activity, and immune response through the degradation of specific intracellular signalling proteins. Inhibition of CBL-B with NX-0255 increases those protein levels and is used to generate a drug-enhanced cell therapy product with superior anti-tumor activity in animal models of adoptive cell therapy. Nurix expects to provide a clinical update from the safety run-in portion of the Phase 1 study in the second half of 2022.

Our preclinical models of adoptive T-cell therapy demonstrate that NX-0255 treatment of cells provides improved characteristics that have the potential to increase the success of manufacturing durable cells that can deliver significant anti-tumor effects, said Michael T. Lotze, M.D., chief cellular therapy officer of Nurix. DeTIL-0255 is an autologous TIL product that is designed to overcome the major limitations of current TIL therapy which include T cell exhaustion post expansion, suboptimal manufacturing success rates, and poor persistence of anti-tumor cells in the patient.

About DeTIL-0255The DeTIL-0255 investigational product under development is an autologous cell therapy consisting of T cells derived from a patients tumor expanded in culture with recombinant interleukin-2 and the small molecule CBL-B inhibitor NX-0255. DeTIL-0255 is designed to be a single administration autologous TIL therapy infused following non-myeloablative chemotherapy. Given the improved phenotypes of T cells produced with CBL-B inhibition, DeTIL-0255 could allow a broader application of TIL therapy, potentially providing long term benefit to patients with multiple types of cancer. Nurix is conducting the open label Phase 1 trial of DeTIL-0255 at multiple sites in the United States. Additional information on the clinical trial can be accessed at http://www.clinicaltrials.gov (NCT05107739).

About Nurix Therapeutics, Inc.Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurixs extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurixs drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurixs wholly owned pipeline includes targeted protein degraders of Brutons tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com/.

Forward Looking StatementThis press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words anticipate, believe, could, estimate, expect, intend, may, outlook, plan, predict, should, will, and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurixs expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective drug candidates; the planned timing and conduct of our clinical trial programs for our drug candidates; the planned timing for the provision of clinical updates and initial findings from our clinical studies; the potential advantages of our DELigase platform and drug candidates; and the extent to which our scientific approach and DELigase platform may potentially address a broad range of diseases. Forward-looking statements reflect Nurixs current beliefs, expectations, and assumptions regarding the future of Nurixs business, future plans and strategies, its development plans, its preclinical and clinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurixs actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) risks and uncertainties related to Nurixs ability to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) the timing and results of preclinical studies and clinical trials; (iii) Nurixs ability to fund development activities and achieve development goals; (iv) the impact of the COVID-19 pandemic on Nurixs business, clinical trials, financial condition, liquidity and results of operations; (v) Nurixs ability to protect intellectual property and (vi) other risks and uncertainties described under the heading Risk Factors in Nurixs Annual Report on Form 10-K for the fiscal year ended November 30, 2021 and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:

Continued here:
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid...

Posted in Cell Therapy | Comments Off on Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid…

Page 498«..1020..497498499500..510520..»